I mean, how does this kind of change your approach to sequencing to some of the points that Rahul made?

Yeah, Monty, I mean, as Rahul said, you know, the field is, is really advancing, and we're using these therapies earlier.

And it's really the lymphoma fit space and the myeloma field that have accumulated the most data showing really an overall survival benefit of CAR T-cell therapy, especially in randomized studies in earlier relapse disease.

So the CARTITUDE-4 study looked at cilta-cel, and the KarMMa-3 study looked at ida-cel, and both demonstrated regression-free survival advantage of these anti-BCMA CAR T-cells compared with your standard IMiD proteasome inhibitor combinations in patients with median of two to three prior lines of therapy where they're currently approved.

And in fact, cilta-cel in an updated analysis showed an overall survival benefit, including in high-risk patients.

So, you know, although these two CAR T products have slightly different adverse event profiles, uh, especially in terms of the timing, grade of CRS and neurological toxicity, they clearly represent a significant milestone in advancing the field.

And I, I think as, as Rahul was alluding to, there are novel CAR T products such as anito-cel, which appear to have an even more favorable adverse event profile.

Is that something that represents the future of myeloma perhaps?

Um, my first time here at ASCO and being part of this great meeting, and I'm very excited to be here.

Great.

So we're gonna kick it off, um, wh-- uh, by starting with, um, two abstracts that I'll start the presentation for.

Then Dr. Zahid will do, uh, two abstracts, uh, and then we'll discuss each one, one at a time.

Um, and these are all, uh, focused on hematologic malignancies, uh, covering a broad spectrum of, uh, hem malignancies.

So let's start off at Abstract seventy-five twelve.

This is belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in, uh, transplant-ineligible, newly diagnosed multiple myeloma patients, a Phase one slash two BeLA-DRd study.

And so I can see that it would be used in, you know, earlier lines of therapy in comparison to, like I said.